GlassScriptPhysician profile
Hugo Manco
NPI 1932734985
$3,319.15
in general payments reported to CMS, 2019-2025
23 companies · $629 in 2025
The $629 reported for 2025 was more than what 75% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $736 · 2022: $526 · 2023: $528 · 2024: $901 · 2025: $629.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,888 · Education: $169.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,888.44 |
| Education | $168.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $545.76 | 2024-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| Boehringer Ingelheim Pharmaceuticals, INC. | $455.92 | 2021-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $409.85 | 2021-2024 | Xarelto |
| Actelion Pharmaceuticals US, INC. | $270.24 | 2023-2025 | Opsumit, Uptravi |
| Astrazeneca Pharmaceuticals LP | $256.72 | 2021-2025 | |
| Impulse Dynamics (USA) INC. | $196.29 | 2024-2025 | Optimizer |
| Novo Nordisk INC | $193.48 | 2022-2025 | Wegovy |
| Amgen INC. | $138.37 | 2021-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $134.05 | 2022-2025 | Camzyos, Eliquis |
| Alnylam Pharmaceuticals INC. | $104.87 | 2024-2025 | Amvuttra, Onpattro |
| Pfizer INC. | $83.16 | 2023-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $77.78 | 2021-2023 | Lifevest |
| Novartis Pharmaceuticals Corporation | $71.74 | 2023-2024 | |
| Chiesi USA, INC. | $66.06 | 2021-2022 | |
| Daiichi Sankyo INC. | $57.41 | 2023-2024 | Injectafer, Vanflyta |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $57.01 | 2022-2025 | Verquvo, Capvaxive |
| Bridgebio Pharma, INC. | $35.85 | 2025 | Attruby |
| Bayer Healthcare Pharmaceuticals INC. | $35.53 | 2024-2025 | |
| Edwards Lifesciences Corporation | $33.50 | 2022 | |
| Endotronix, INC. | $31.17 | 2025 | Cordella Pulomonary Artery Pressure Sensor |
| Lexicon Pharmaceuticals, INC. | $29.30 | 2023 | Inpefa |
| United Therapeutics Corporation | $18.47 | 2025 | Tyvaso |
| Medtronic, INC. | $16.62 | 2024 | Corevalve Evolut R |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hugo Manco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.